4DMedical Limited (FDMDF) Stock

About 4DMedical Limited

4DMedical Limited operates as a medical technology firm with operations spanning both Australia and the United States. A core aspect of its business involves the commercialization of XV Technology, an advanced four-dimensional system for lung imaging. The company's offerings further extend to a software-as-a-service (SaaS) delivery model, alongside its proprietary XV lung ventilation analysis software. Additional products include Permetium, a preclinical imaging system designed to quantify localized changes in pulmonary function, and the AccuVent 200, a ventilator specifically tailored for small animals. Established in 2012, 4DMedical Limited is headquartered in Carlton, Australia.

4DMedical Limited is headquartered in AU.

4DMedical Limited (FDMDF) stock trades at $2.53 with a market capitalization of $1.52B. The stock is valued at a negative price-to-earnings (P/E) ratio of -12.25, reflecting a net loss over the last twelve months, a negative price-to-book of -69.10, reflecting negative shareholders' equity, price-to-sales of 548.23. Over the past 52 weeks the stock has ranged between $0.16 and $5.00, and currently trades 49.4% below its 52-week high.

On profitability, 4DMedical Limited generates a return on equity (ROE) of -890.76% (not meaningful, as shareholders' equity is negative), return on capital employed of -38.89%, an operating margin of -483.33%, a net profit margin of -500.00%.

Official website: www.4dmedical.com